Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2027 of 6351
-
Pee power: urine test could spot kidney cancer without needles
Diagnosis Recruiting nowClear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. This diagnosis is expensive, invasive and sometimes late. The development of a simple biological test for diagnosis is essential. Exosomes are 30 to 150 nm membrane vesicles secreted into t…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Stopped earlyThis dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and lymphatic malignancies positive for CD123 marker. The Uni…
Phase 1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New resilience program aims to help african americans take control of diabetes
Disease control OngoingAfrican Americans are twice as likely to have type 2 diabetes as non-Hispanic Whites and are less likely to engage in effective diabetes self-management. There is a critical need for intensive lifestyle interventions that address the distress inherent in having the disease and th…
Sponsor: University of Texas at Austin • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can a DNA-Enriched mouthwash tame gum disease biofilm?
Disease control CompletedSodium DNA has several properties that may be beneficial in the management of bacterial biofilm in periodontitis. The aim of this RCT study is to clinically evaluate the antimicrobial and oral biofilm control properties of two mouthwashes containing Chlorhexidine 0.2% + Sodium DN…
Sponsor: University of Catania • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Gene therapy for rare brain disease tracked over years
Disease control OngoingThis is a long-term safety and efficacy study in subjects with CLN6 Batten disease who previously received a single intrathecal administration of AT-GTX-501.
Sponsor: Emily de los Reyes • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New dissolving film could calm agitation in schizophrenia without needles
Symptom relief CompletedThis is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) …
Phase 3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Bacteria cocktail aims to boost cancer immunotherapy
Disease control CompletedThis study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
Phase 1/2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Poop pills may prevent dangerous side effects of cancer immunotherapy
Disease control OngoingCancer immunotherapy has been largely adopted in oncology patient management in the last decade. The deep and long responses to immunotherapy have accelerated the approval of these drugs across multiple disease sites. However, these agents can also be toxic to patients, meaning, …
Phase 1 • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 26, 2026 17:19 UTC
-
Can we unmask the hidden interference in filariasis testing?
Knowledge-focused CompletedThis prospective study will enroll and follow 60 loiasis patients with high worm burden to monitor the spontaneous release of filarial antigen in peripheral blood. This study will define the cross-reactive antigen profile of persons with spontaneous loiasis antigenemia, and deter…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can light therapy soothe the brain? a pupil test holds clues
Knowledge-focused Recruiting nowThe light has visual and non-visual effects on organism and can act on the behavior, the mood, the cognition and the sleep. These effects are mediated by "classical" retina photoreceptors which allow vision (rods, cones) but also melanopsin cells. The non-visual effects of light …
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Brain Radio' trial hopes to crack code of depression treatment
Disease control OngoingOf the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depr…
Sponsor: Helen Mayberg, MD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for kids with severe psoriasis: drug trial underway
Disease control CompletedThe purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy shows promise for tough lung cancers
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This stud…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Scientists probe Ketamine's Fast-Acting depression relief in brain receptor study
Knowledge-focused Recruiting nowBackground: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works. Objective: To see …
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to predict dangerous side effects of cancer immunotherapy
Knowledge-focused Recruiting nowImmune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related advers…
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
New hip cup design aims to stop common complication in elderly fracture patients
Disease control CompletedOur aim is to develop a strategy that reduces the risk of dislocations after total hip arthroplasty surgery performed due to femoral neck fracture. We therefore perform a register-nested, pragmatic, randomized controlled trial to investigate the safety and efficacy of dual mobili…
Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control CompletedThis phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in…
Phase 2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cancer drug zanubrutinib tested for Long-Term safety in 955 patients
Disease control OngoingThe purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for kids with severe psoriasis: drug trial shows promise
Disease control OngoingThe study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiati…
Phase 2/3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a simple blood test outsmart prostate cancer?
Knowledge-focused By invitation onlyProstate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT). Survival is linked to early and accurate diagnoses or to …
Sponsor: Wren Laboratories LLC • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC